Company profile

Shenzhen Ionova Life Sciences Co., Ltd.

Privately held: no public share price (Privately held; raised a $100M private round in Aug 2021 led by Tsing Song Capital and Shenzhen Capital Group. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/ionova-life-science-announces-new-financing-round-of-usd-100-million-301364350.html]) · China

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
INV-6452
Phase 2
CDK2/CDK4Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
INV-8989
Phase 2
KRAS G12DSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.